Page 121 - Read Online

Simsek et al. Hepatoma Res 2020;6:11 I http://dx.doi.org/10.20517/2394-5079.2019.51 Page 7 of 10

1
7
5
3
2
9
8
4
6
11
15
16
17
19
18
21
14
12
13
23
10
24
26
22
25
20
Patient
1
1
1
1
1
1
1
1
1
5
8
2
2
5
5
5
3
3
2
5
3
lesions
Infiltrative
Infiltrative
Infiltrative
Infiltrative
Infiltrative
Number of
1
1
2
4
2
8
4
6
5
19
1.1
7.5
7.5
1.6
1.5
3.5
2.8
7.2
2.9
8.5
3.5
2.6
2.3
2.2
2.8
4.3
Largest
lesion (cm)
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
criteria
Within Milan
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
Yes
Yes
Yes
Yes
Downstaged
No
No
No
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
duct)
MVI
Table 3. Specific characteristics of the tumors, treatment, and outcomes
Yes (bile
Poor
Poor
Poor
Poor
Poor
Poor
Poor
Poor
Poor
Poor
Poor
Moderate
Moderate
Moderate
Moderate
Moderate
Moderate
Moderate
Moderate
Moderate
Moderate
Moderate
Moderate
Moderate
Moderate
No viable tissue
microvascular invasion; RFA: radiofrequency ablation; TACE: transarterial chemoembolization
Differentiation
94
78
111
34
93
80
713
291
261
147
199
314
102
917
795
594
346
536
224
950
482
490
984
464
544
1502
following LT (in days)
Diagnosis of recurrence
Liver
Liver
Liver
Liver
Liver
Spine
Liver
Brain
Brain
Bile ducts
Lung, liver
Bone, lung
Ribs, spine
Pelvic bone
Portal nodes,
nodes, pleura
Perihilar, lung
Porta-hepatis
carcinomatosis
Gastro-hepatic
Humerus, brain
Lung, peritoneal
Lung, bone, liver
mediastinal, lung
Pelvic bone, lung
Lung, mediastinal
Spine, mediastinal
Mediastinal lymph
Brain, liver, adrenal
Site of recurrence
ligament, mediastinal
Died
Died
Died
Died
Died
Died
Died
Alive
Alive
Died
Died
Died
Died
Died
Died
Died
Died
Died
Died
Died
Died
Died
Died
Died
Died
Died
Survival
-
-
178
861
1131
697
369
493
332
547
253
222
663
366
1319
602
407
260
780
1156
1065
1359
1459
1079
1062
1466
Time of death
following LT (days)
Y90
TACE
TACE
in liver
Sorafenib
Sorafenib
Sorafenib
capecitabine
Spine radiation
Supportive care
Supportive care
Supportive care
Supportive care
Supportive care
Supportive care
External radiation
External radiation
external radiation
brain met resection
Chemotherapy with
Chemotherapy with
RFA, TACE, Sorafenib
Gemcitabine/Cisplatin,
Brain metastasis resection
Brain metastasis resection
Brain metastasis resection
of adrenal metastasis, Y90
and radiation, cryoablation
Whipple surgery, Sorafenib
Spine surgery and radiation
Spine surgery and radiation
Treatment of recurrence
External radiation, Sorafenib
Sorafenib, external radiation
Bone resection and radiation,
Specific characteristics of the tumors, treatment, and outcomes in 26 liver transplant recipients with a recurrence of hepatocellular carcinoma following liver transplant. LT: liver transplant; MVI: